{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:01:42Z","timestamp":1762077702900,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL110837"],"award-info":[{"award-number":["T32HL110837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ahj.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T18:07:46Z","timestamp":1556302066000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status"],"prefix":"10.1016","volume":"214","author":[{"given":"Mohammed","family":"Qintar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne V.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Sheehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sapontis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Karmpaliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Aaron","family":"Grantham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.04.013_bb0005","unstructured":"Sapontis J, Salisbury AC, Yeh RW, et al. Early procedural and health status outcomes after chronic total occlusion angioplasty: a report from the OPEN-CTO registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. Aug 14 2017;10(15):1523\u20131534."},{"key":"10.1016\/j.ahj.2019.04.013_bb0010","doi-asserted-by":"crossref","unstructured":"Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. Nov 04 2014;64(18):1929\u20131949.","DOI":"10.1161\/CIR.0000000000000095"},{"key":"10.1016\/j.ahj.2019.04.013_bb0015","unstructured":"Coronary Revascularization Writing G, Patel MR, Dehmer GJ, et al. ACCF\/SCAI\/STS\/AATS\/AHA\/ASNC\/HFSA\/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. The Journal of thoracic and cardiovascular surgery. Apr 2012;143(4):780\u2013803."},{"issue":"4","key":"10.1016\/j.ahj.2019.04.013_bb0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCOUTCOMES.113.000139","article-title":"Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial","volume":"6","author":"Spertus","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2019.04.013_bb0025","doi-asserted-by":"crossref","unstructured":"Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. Oct 9 2013;168(4):3572\u20133579.","DOI":"10.1016\/j.ijcard.2013.05.068"},{"issue":"12","key":"10.1016\/j.ahj.2019.04.013_bb0030","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/14740338.2016.1238457","article-title":"The risk of cardiovascular side effects with anti-anginal drugs","volume":"15","author":"Rousan","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ahj.2019.04.013_bb0035","doi-asserted-by":"crossref","unstructured":"Rayner-Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc. Mar 15 2016;5(3):e003196.","DOI":"10.1161\/JAHA.116.003196"},{"key":"10.1016\/j.ahj.2019.04.013_bb0040","unstructured":"McDonagh MS, Eden KB, Peterson K. Drug class review: calcium channel blockers: final report. Portland (OR)2005."},{"key":"10.1016\/j.ahj.2019.04.013_bb0045","doi-asserted-by":"crossref","unstructured":"Safley DM, Grantham JA, Hatch J, Jones PG, Spertus JA. Quality of life benefits of percutaneous coronary intervention for chronic occlusions. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. Oct 01 2014;84(4):629\u2013634.","DOI":"10.1002\/ccd.25303"},{"key":"10.1016\/j.ahj.2019.04.013_bb0050","doi-asserted-by":"crossref","unstructured":"Olivari Z, Rubartelli P, Piscione F, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). Journal of the American College of Cardiology. May 21 2003;41(10):1672\u20131678.","DOI":"10.1016\/S0735-1097(03)00312-7"},{"issue":"1","key":"10.1016\/j.ahj.2019.04.013_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcin.2007.11.003","article-title":"Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility: insights from quantitative cardiovascular magnetic resonance imaging","volume":"1","author":"Cheng","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2019.04.013_bb0060","doi-asserted-by":"crossref","unstructured":"Qintar M, Towheed A, Tang F, et al. The Impact of de-escalation of antianginal medications on health status after percutaneous coronary intervention. J Am Heart Assoc. Oct 20 2017;6(10).","DOI":"10.1161\/JAHA.117.006405"},{"key":"10.1016\/j.ahj.2019.04.013_bb0065","unstructured":"Sapontis J, Marso SP, Cohen DJ, et al. The outcomes, patient health status, and efficiency in chronic total occlusion hybrid procedures registry: rationale and design. Coronary artery disease. Oct 13 2016."},{"key":"10.1016\/j.ahj.2019.04.013_bb0070","doi-asserted-by":"crossref","unstructured":"Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. The American journal of cardiology. Dec 15 1994;74(12):1240\u20131244.","DOI":"10.1016\/0002-9149(94)90555-X"},{"issue":"2","key":"10.1016\/j.ahj.2019.04.013_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","article-title":"Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease","volume":"25","author":"Spertus","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2019.04.013_bb0080","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/CIRCOUTCOMES.114.000967","article-title":"Development and validation of a short version of the Seattle angina questionnaire. Circulation","volume":"7","author":"Chan","year":"2014","journal-title":"Cardiovascular quality and outcomes."},{"issue":"8","key":"10.1016\/j.ahj.2019.04.013_bb0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jcin.2014.04.005","article-title":"Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis","volume":"7","author":"Babaliaros","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.ahj.2019.04.013_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCOUTCOMES.108.829523","article-title":"Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circulation","volume":"2","author":"Arnold","year":"2009","journal-title":"Cardiovascular quality and outcomes"},{"issue":"6","key":"10.1016\/j.ahj.2019.04.013_bb0095","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/CIRCOUTCOMES.113.000752","article-title":"Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial","volume":"7","author":"Arnold","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2019.04.013_bb0100","doi-asserted-by":"crossref","unstructured":"Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation. Dec 21 2004;110(25):3789\u20133794.","DOI":"10.1161\/01.CIR.0000150392.70749.C7"},{"key":"10.1016\/j.ahj.2019.04.013_bb0105","first-page":"1","article-title":"Cardiovascular survey methods","volume":"56","author":"Rose","year":"1968","journal-title":"Monogr Ser World Health Organ"},{"issue":"6","key":"10.1016\/j.ahj.2019.04.013_bb0110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2009.03.021","article-title":"The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry","volume":"157","author":"Arnold","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.04.013_bb0115","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. Jama. May 26 1999;281(20):1927\u20131936.","DOI":"10.1001\/jama.281.20.1927"},{"key":"10.1016\/j.ahj.2019.04.013_bb0120","unstructured":"(UK) RCoP. Stable angina: methods, evidence & guidance [Internet]. National Clinical Guidelines Centre (UK). 2011;NICE Clinical Guidelines, No. 126."},{"issue":"18","key":"10.1016\/j.ahj.2019.04.013_bb0125","doi-asserted-by":"crossref","first-page":"B205","DOI":"10.1016\/j.jacc.2017.09.609","article-title":"TCT-496 predictors of residual angina after chronic total occlusion percutaneous coronary intervention: external validation of an existing model","volume":"70","author":"Qintar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.04.013_bb0130","doi-asserted-by":"crossref","unstructured":"Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. The New England journal of medicine. Aug 14 2008;359(7):677\u2013687.","DOI":"10.1056\/NEJMoa072771"},{"year":"2015","series-title":"Graham G","author":"Arnold","key":"10.1016\/j.ahj.2019.04.013_bb0135"},{"key":"10.1016\/j.ahj.2019.04.013_bb0140","doi-asserted-by":"crossref","unstructured":"Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Archives of internal medicine. Jun 23 2008;168(12):1310\u20131316.","DOI":"10.1001\/archinte.168.12.1310"},{"key":"10.1016\/j.ahj.2019.04.013_bb0145","doi-asserted-by":"crossref","unstructured":"Arnold SV, Masoudi FA, Rumsfeld JS, Li Y, Jones PG, Spertus JA. Derivation and validation of a risk standardization model for benchmarking hospital performance for health-related quality of life outcomes after acute myocardial infarction. Circulation. Jan 21 2014;129(3):313\u2013320.","DOI":"10.1161\/CIRCULATIONAHA.113.001773"},{"key":"10.1016\/j.ahj.2019.04.013_bb0150","doi-asserted-by":"crossref","unstructured":"Alexander KP, Weisz G, Prather K, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) trial. Circulation. Jan 05 2016;133(1):39\u201347.","DOI":"10.1161\/CIRCULATIONAHA.115.019768"},{"key":"10.1016\/j.ahj.2019.04.013_bb0155","doi-asserted-by":"crossref","unstructured":"Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. Jul 7 2018;39(26):2484\u20132493.","DOI":"10.1093\/eurheartj\/ehy220"},{"issue":"1","key":"10.1016\/j.ahj.2019.04.013_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.socscimed.2004.11.063","article-title":"Resisting medicines: a synthesis of qualitative studies of medicine taking","volume":"61","author":"Pound","year":"2005","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1016\/j.ahj.2019.04.013_bb0165","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ahj.2010.12.005","article-title":"Angina frequency after myocardial infarction and quality of life in older versus younger adults: the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study","volume":"161","author":"Longmore","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.04.013_bb0170","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. Bmj. Jan 16 2013;346:f55.","DOI":"10.1136\/bmj.f55"},{"issue":"10","key":"10.1016\/j.ahj.2019.04.013_bb0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:50Z","timestamp":1762077410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319301024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":35,"alternative-id":["S0002870319301024"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.04.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}